GlassScriptPhysician profile
Dianne Goodale
NPI 1497851562
$8,595.75
in general payments reported to CMS, 2019-2025
39 companies · $1,874 in 2025
The $1,874 reported for 2025 was more than what 96% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $523 · 2021: $838 · 2022: $727 · 2023: $1,476 · 2024: $1,816 · 2025: $1,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,134 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,134.14 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,888.08 | 2019-2025 | |
| Pfizer INC. | $1,009.67 | 2019-2025 | |
| Novo Nordisk INC | $873.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $636.65 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $536.11 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $481.46 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Axsome Therapeutics, INC. | $334.99 | 2023-2025 | Auvelity, Symbravo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.39 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $296.79 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $276.94 | 2019-2023 | Spravato |
| Glaxosmithkline, LLC. | $215.20 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $195.45 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.20 | 2019-2023 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $182.56 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $167.54 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dianne Goodale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.